The Latest Breaking News from Oncology

With the rising prevalence of chronic diseases, increasing cell and gene therapies, and rising tech adoption in the biotech industry, the oncology market is booming. Amid this backdrop, investors could consider quality biotech stocks Pyxis Oncology (PYXS), Immatics (IMTX), and Jazz Pharmaceuticals (JAZZ), having significant upside potential. Continue reading.

A new generation of radiotherapies are redefining cancer care, offering the potential for a more powerful treatment with fewer side effects. It could become a mainstream therapy for the big "traditional" cancers that make the disease the leading cause of death worldwide, which is why Morgan Stanley forecast the radiopharma…

Sanjay Kumar arrested in Houston for selling counterfeit cancer drugs in the U.S., facing serious charges for trafficking in fake oncology medications.

Cancer is one of the most devastating diseases, affecting thousands of people every year. That is also why it is one of the most well-researched areas of healthcare, with medical professionals constantly looking for ways to adapt the latest technology developments to improve cancer detection and treatments

As the biotech industry continues to redefine the healthcare landscape, here are five penny biotech stocks poised for meteoric growth in this evolving industry.

The annual conference of the American Society of Clinical Oncology is always the biggest event-making cancer conference. And this year, the attention-grabber was AstraZeneca, as its lung and breast cancer drugs significantly slowed the spread of disease in two trials, potentially establishing the medicines as the new standard of care…

World’s largest cancer conference in Chicago shares ‘impressive’ findings in vaccines, drug trials and AI

‘They didn’t even try to make it work,’ one oncology patient said of Memorial Medical Center

The pharmaceutical industry is expected to grow rapidly due to the ever-rising healthcare needs, increasing demand for innovative medications, and technological advancements. Therefore, fundamentally strong pharmaceutical stocks Dr. Reddy’s (RDY), Teva Pharmaceutical Industries (TEVA), and AbbVie (ABBV) could be worth adding to your portfolio. Read on.

Despite its outsized year-to-date gains, Wall Street expects this breakout penny stock to soar 55% higher, on average.

Next-generation cancer therapies are here. AstraZeneca - already an oncology leader - is going down the path of radiopharmaceuticals with its purchase of Fusion. Along with the other potential blockbuster drugs in its pipeline, this should bode well for growth at AZN.